drugset / Trial / NCT04092595

A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants

NCT04092595

Phase 1 Completed 12 enrolled Pfizer
NaSingle-groupOpen-labelBasic science

Summary

A phase 1, 2-period, fixed-sequence, multiple-dose, open-label study of the effect of PF-06651600 on Rosuvastatin pharmacokinetics in healthy participants. Approximately 12 healthy male and/or female participants will be enrolled in the study.

Timeline

Start
2019-09-26
Primary completion
2020-01-15
Completion
2020-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritlecitinib Small molecule 200 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral

Indications

No indication recorded.